Preservation of genome integrity is a priority issue in mammalian tissues, especially in the nervous system, where a defective DNA damage response (DDR) is associated with developmental and neoplastic disorders. Recently, our work focused on the functional interactions between MYCN and the replication stress (RS)-response in neuronal cells. We showed that MYCN regulates the expression of a number of proteins, including the MRN complex and PARP, to control RS, prevent DNA damage and cell death. Moreover, inhibition of either MRN or PARP+CHK1 very effectively kills MYCN-dependent neuroblastoma (NB) and medulloblastoma (MB), tumors that are still largely incurable.
Based on our own and other's work we generated some testable hypotheses: i) the MRN complex is essential to control RS in neuronal progenitors; ii) subtle variations in MRN activity may uncover its oncosuppressive function in neuronal tumorigenesis; iii) MYCN-dependent neoplastic cells retain a strict requirement for controlling the otherwise deleterious effects of RS; iv) MYCN supports a coordinated pattern of replication-, DNA repair- and checkpoint-related genes whose pharmaceutical modulation might be of utmost importance for the therapy of MYCN-overexpressing tumors.
We will test these hypothesis via pharmacological and genetic manipulations of designed targets in NB and MB animal and cell models. Through dry and wet lab work, we will further screen for more effective combinations of "RS-response" inhibitors.
We expect our efforts will provide: i) an increased understanding of the molecular mechanisms linking oncogene-induced RS and neuronal carcinogenesis; ii) a proof of concept for a novel therapeutic approach for MYCN-overexpressing tumors; iii) a number of validated animal and cellular models for further studies. Finally, by showing that targeting the "RS response" is feasible and effective, we will hopefully establish a novel approach for the therapy of deadly tumors, such as MYCN-amplified NB.
Understanding the role of DNA repair factors involved in controlling RS in the CNS is pivotal to comprehend how and why DDR-defective syndromes so vastly affect the nervous system. Our work partially focuses on this issue and hopefully will provide important hints for a better understanding of these diseases. Moreover, uncovering the relationships between MYCN (a protoncogene) and DNA repair factors (i.e. the MRN complex, PARP) will have a strong impact on basic biological questions concerning CNS development and differentiation.
Most importantly, however, we know that MNA neuroblastoma, and more in general MYCN-dependent tumors, display a very aggressive phenotype. Since biological therapies specifically targeting MYCN are not available at the moment, the survival of these patients remains extremely poor. This makes the search for new therapeutic approaches an absolute priority. We have already offered a proof of principle that targeting MYCN-dependent RS might be effective against MNA neuroblastoma and a large part of the project aims to further support this hypothesis. In addition, since PARP and CHK1 inhibitors have been approved for use in human beings, should our data be confirmed in animal models, the results can be immediately translated into clinical trials.
Therefore, not only our data have the possibility to provide significant advancements in knowledge, but might also be able to indicate a novel therapy for deleterious childhood tumors.
Moreover, the project will help developing and characterizing a number of new tools, including animal models (SmoA1/Nbn+/--CNS-Del mouse; Gli1-CreERT1/NBNfl/fl mouse), cell models (Hhact-GCP neurospheres from different sources) and bioinformatic tools, which will be available for further studies in our and other research groups.
REFERENCES
1. Halazonetis, TD, et al. (2008). Science. 319, 1352-5.
2. Bartkova, J, et al. (2005). Nature. 434, 864-70.
3. Murga, M, et al. (2011). Nat Struct Mol Biol. 18, 1331-5.
4. Stracker, TH, et al. (2011). Nature reviews Molecular cell biology. 12, 90-103.
5. Trenz, K, et al. (2006). Embo J. 25, 1764-74.
6. Bryant, HE, et al. (2009). Embo J. 28, 2601-15.
7. Schlacher, K, et al. (2011). Cell. 145, 529-42.
8. Frappart, PO, et al. (2005). Nat Med. 11, 538-44.
9. Knoepfler, PS, et al. (2002). Genes Dev. 16, 2699-712.
10. Petroni, M, et al. (2016). Cell Death Differ. 23, 197-206.
11. Bruhn, C, et al. (2014). Cell reports. 6, 182-95.
12. Frappart, PO, et al. (2007). Embo J. 26, 2732-42.
13. Miele, E, et al. (2015). Biomarker research. 3, 13.
14. Huang, J, et al. (2008). Clin Cancer Res. 14, 4053-8.
15. Giannini, G, et al. (2004). Oncogene. 23, 2640-7.
16. Giannini, G, et al. (2002). EMBO Rep. 3, 248-54.
17. Ottini, L, et al. (2004). Carcinogenesis. 25, 2337-43.
18. Gupta, GP, et al. (2013). Molecular cell. 52, 353-65.
19. Yang, MH, et al. (2007). Oncogene. 26, 1459-67.
20. Yang, MH, et al. (2006). Clin Cancer Res. 12, 507-15.
21. Colicchia, V, et al. (2017). Oncogene.
22. Petroni, M, et al. (2017). In preparation.
23. Swartling, FJ, et al. (2012). Cancer cell. 21, 601-13.
24. Paci, P, et al. (2017). Sci Rep. 7, 44797.